Peanut Allergy Treatment Global Market Report 2024

The peanut allergy treatment market size has grown rapidly in recent years. It will grow from $0.41 billion in 2023 to $0.45 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to increased prevalence, advancements in diagnostic testing, growing public awareness and concern, the development of early intervention strategies, and regulatory approvals for peanut allergy treatments.

The peanut allergy treatment market size is expected to see rapid growth in the next few years. It will grow to $0.69 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to a continued rise in prevalence, the expansion of personalized medicine approaches, the introduction of novel immunotherapy treatments, growth in public and private investment, and the expansion of telemedicine services. Major trends expected in the forecast period include increased adoption of immunotherapy, advancements in biologic therapies, integration of probiotic-based treatments, technological innovations in delivery systems, personalized medicine approaches, and regulatory approvals and support.

Investments in research and development for allergy treatments are poised to propel the growth of the peanut allergy treatment market. Research and development (R&D) investments, involving financial resources directed toward innovation and product development, are crucial for advancing therapies for peanut allergies. These investments drive the creation of innovative immunotherapies and desensitization techniques aimed at reducing allergic reactions and enhancing the quality of life for individuals affected by peanut allergies. For instance, in January 2024, the Victorian Government announced a strategic $12 million investment in Aravax, an Australia-based biotechnology company, to advance global peanut allergy treatment. This funding, part of a broader $66 million initiative, supports the development of Aravax's innovative immunotherapy, PVX108, with Phase 2 trial approvals from the U.S. FDA and Australia’s TGA highlighting its potential impact on public health worldwide. Thus, research and development investments in allergy treatments are fueling the growth of the peanut allergy treatment market.

Key players in the peanut allergy treatment market are prioritizing the development of biologic therapies, such as anti-IgE monoclonal antibodies, to offer more targeted and effective solutions for managing peanut allergies and improving patient outcomes. These antibodies are designed to target and neutralize immunoglobulin E (IgE) antibodies in the body. For example, in February 2024, Novartis Pharmaceuticals Corporation received FDA approval for Xolair (omalizumab), intended to reduce allergic reactions, including anaphylaxis, in patients with IgE-mediated food allergies. The approval, based on data from the NIH-sponsored Phase III OUtMATCH study, underscores significant improvement in food allergy tolerance among patients treated with Xolair compared to those receiving a placebo.

In September 2023, Stallergenes Greer International AG acquired the peanut allergy drug Palforzia from Nestlé S.A. for an undisclosed amount. This acquisition expands Stallergenes Greer's anti-allergy portfolio, complementing its suite of approved products targeting various allergies. Nestlé S.A., a provider of food, beverage, and pharmaceutical products, had developed Palforzia for peanut allergy treatment.

Major companies operating in the peanut allergy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Viatris Inc., Regeneron Pharmaceuticals Inc., Hikma Pharmaceuticals plc, ALK-Abelló A/S, Amneal Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc, Stallergenes Greer plc, kaleo Inc., Aquestive Therapeutics Inc., Vedanta Biosciences Inc., Aimmune Therapeutics Inc., AnaptysBio Inc., Alladapt Immunotherapeutics Inc., Aravax Pty Ltd, Intrommune Therapeutics Inc., IgGenix Inc., DBV Technologies SA, Camallergy Ltd., HAL Allergy Group, Prota Therapeutics Pty Ltd.

North America was the largest region in the peanut allergy treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peanut allergy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peanut allergy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Peanut allergy treatment encompasses various medical approaches aimed at managing and reducing the severity of allergic reactions to peanuts. These treatments include strategies such as epicutaneous immunotherapy and biologic therapies, which are intended to desensitize individuals to peanuts and alleviate allergic reactions.

The main drug classes used in peanut allergy treatment include antihistamines, immunotherapies, epinephrine, and others. Antihistamines are medications that relieve allergy symptoms by blocking the action of histamine, a substance released by the immune system during allergic reactions. These drugs can be administered through injectables, orally, and by other methods. They are typically distributed through retail pharmacies, hospital pharmacies, and other healthcare facilities.

The peanut allergy treatment research report is one of a series of new reports that provides peanut allergy treatment market statistics, including the peanut allergy treatment industry's global market size, regional shares, competitors with a peanut allergy treatment market share, detailed peanut allergy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the peanut allergy treatment industry. This peanut allergy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peanut allergy treatment market consists of revenues earned by entities by providing services such as diagnostic testing, personalized treatment plans, oral immunotherapy sessions, patient education and counseling, monitoring of allergic reactions, and access to emergency care. The market value includes the value of related goods sold by the service provider or included within the service offering. The peanut allergy treatment market also includes sales of allergy drops, allergy tablets, and peanut allergen extract. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.